Michael Sherman, MD, MBA, MS

Bio:

Dr. Michael Sherman is Principal at Sherman Healthcare Solutions, LLC, a firm providing consulting services, fractional executive-level support, and independent board service to the healthcare industry.  He serves as an advisor to multiple investment funds, focusing on healthcare services, life sciences, diagnostics, healthcare technology, and related areas, particularly addressing issues relating to market access, pricing and reimbursement, and he holds a faculty appointment in the Department of Population Medicine at Harvard Medical School.  Prior to May 2025, he spent two years as a full-time venture partner at RA Capital Management, which he still advises.

In 2018, he received Xconomy’s “Contrarian Award” for his contributions, including having developed and executed the nation’s first value-based payment model for a gene therapy, and his work is also featured in a Harvard Business School case study published in 2021.   

Prior to joining RA, Dr. Sherman served as executive vice president and chief medical officer at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan, and before that he was chief medical officer of Harvard Pilgrim Health Care, where he was a leader in expanding access for innovative cell and gene therapies, treatments for rare diseases, and diagnostics through partnering with industry and pioneering value-based payment models.  Dr. Sherman serves on multiple boards of directors and has held executive roles at Humana, United Healthcare, and other well-known companies. Before pursuing an M.B.A. at Harvard Business School, Dr. Sherman received his M.D. from Yale and practiced as a cardiac anesthesiologist. He also holds B.A. and M.S. degrees from the University of Pennsylvania.